Table 1.
Patients’ demographic and disease characteristics at study entry.
| No. 30 (%) | |
|---|---|
| Median Age (years) | 62 (range, 29-79) |
| Sex | |
| Male | 23 (77) |
| Female | 7 (23) |
| Histology | |
| Clear Cell | 26 (87) |
| Papillary 1-2/Others | 4 (13) |
| Karnofsky Performance status | |
| 100% | 17 (57) |
| 80-90% | 7 (23) |
| ⩽70% | 2 (7) |
| Unknown | 4 (13) |
| IMDC score | |
| Good | 5 (17) |
| Intermediate | 16 (53) |
| Poor | 9 (30) |
| Previous therapy | |
| Pembrolizumab-Lenvatinib | 7 (23) |
| Avelumab-Axitinib | 1 (3) |
| Ipilimumab-Nivolumab | 19 (63) |
| Atezolizumab (adjuvant) | 3 (10) |
| Best response to previous therapy | |
| CR | 2 (7) |
| PR | 6 (20) |
| SD | 13 (43) |
| PD | 9 (30) |
| Site of metastasis | |
| Lung | 21 (70) |
| Liver | 4 (13) |
| Lymph nodes | 13 (43) |
| Bone | 4 (13) |
| Brain | 3 (10) |
| Adrenal | 10 (33) |
| Pancreas | 2 (7) |
| Kidney (contralateral) | 3 (10) |
| Others (peritoneum, spleen, pleura, soft tissues) | 7 (23) |
CR, complete response; IMDC, International Metastatic Renal-Cell Carcinoma Database Consortium’s criteria; PD, progressive disease; PR, partial response; SD, stable disease.